Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen

Clinica Chimica Acta

Volumn 413, Issue 5-6, 2012, Pages 561-567

  O'Rourke, Dennis J ^a   DiJohnson, Daniel A ^a   Caiazzo, Robert J ^a   Nelson, James C ^b   Ure, David ^b   O'Leary, Michael P ^a   Richie, Jerome P ^a   Liu, Brian C S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Inanovate Inc   (United States)

Author keywords

Autoantibodies; Biomarkers; Immunomics; Prostate cancer; Prostate specific antigen; Protein microarray

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CALD1 ANTIBODY; PARK7 ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PSIP1 ANTIBODY; TARDBP ANTIBODY; TLN1 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; AUTOANTIBODIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84856221635     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.11.027     Document Type: Article

References (21)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Brawer M.K. Prostate-specific antigen: current status. CA Cancer J Clin 1999, 49:264-281.
3. Gretzer M.B., Partin A.W. PSA markers in prostate cancer detection. Urol Clin North Am 2003, 30:677-686.
4. Finn O.J. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med 2005, 353:1288-1290.
5. Anderson K.S., LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005, 4:1123-1133.
6. Qin S., Qiu W., Ehrlich J.R., et al. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 2006, 6:3199-3209.
7. Ehrlich J.R., Caiazzo R.J., Qiu W., et al. A native antigen "reverse capture" microarray platform for autoantibody profiling of prostate cancer sera. Proteomics Clin Appl 2007, 1:476-485.
8. Ehrlich J.R., Qin S., Liu B.C.S. The "reverse capture" autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 2006, 1:452-460.
9. Wang X., Yu J., Sreekumar A., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005, 353:1224-1235.
10. Buratti E., Dork T., Zuccato E., Pagani F., Romano M., Baralle F.E. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 2001, 20:1774-1784.
11. Ayala Y.M., Misteli T., Baralle F.E. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A 2008, 105:3785-3789.
12. Taylor B.S., Pal M., Yu J., et al. Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics 2008, 7:600-611.
13. Sakamoto S., McCann R.O., Dhir R., Kyprianou N. Talin 1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 2010, 70:1885-1895.
14. Niki T., Takahashi-Niki K., Taira T., Iguchi-Ariga S.M.M., Ariga H. DJBP: a novel DJ-1 binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. Mol Cancer Res 2003, 1:247-261.
15. Ronquist K.G., Carlsson L., Ronquist G., Nilsson S., Larsson A. Prostasome-derived proteins capable of eliciting an immune response in prostate cancer patients. Int J Cancer 2006, 119:847-853.
16. Daniels T., Zhang J., Gutierrez I., et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005, 62:14-26.
17. Zheng P.P., van der Weiden M., Kros J.M. Differential expression of HeLa-type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cells. J Pathol 2005, 205:408-414.
18. Yoshio T., Morita T., Kimura Y., Tsujii M., Hayashi N., Sobue K. Caldesmon suppresses cancer cell invasion by regulating podosome/invadopodium formation. FEBS Lett 2007, 581:3777-3782.
19. Zhang J.Y., Casiano C.A., Peng X.X., Koziol J.A., Chan E.K., Tan E.M. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003, 12:136-143.
20. Zhang J.Y. Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Cancer Detect Prev 2004, 28:114-118.
21. Casiano C.A., Mediavilla-Varela M., Tan E.M. Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 2006, 5:1745-1759.